# US 2024/0390375 A1 · Methods and compositions for treating viral or virally-induced conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390375 A1
- Document ID: US20240390375A1
- Status: Published application
- Kind: A1
- Application number: 18/796,094
- Filed: 2024-08-06
- Published: 2024-11-28
- Earliest claimed: 2010-03-11
- Assignees: Viracta Subsidiary, Inc.; Trustees of Boston University
- Applicants: Viracta Subsidiary, Inc.; Trustees of Boston University
- Inventors: Ronald J. Berenson; Douglas V. Faller
- Web page: https://patentgrep.com/patent/US20240390375A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/52: Purines, e.g. adenine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/15: Depsipeptides; Derivatives thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.

## Claims

### Claim 1

A method for treating and/or preventing a viral or virally-induced condition comprising administering a HDAC inhibitor and an antiviral agent wherein the viral or virally-induced condition is caused by a DNA virus and the HDAC inhibitor is administered at dose of less than 2 mg/kg per dose.

### Claim 2 (depends on 1)

The method of claim 1, wherein the HDAC inhibitor is Vorinostat/suberoyl anilide hydroxamic acid, JNJ-26481585 ((N-hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide), R306465/JNJ-16241199 (N-hydroxy-5-(4-(naphthalen-2-ylsulfonyl)piperazin-1-yl)pyrimidine-2-carboxamide), or CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide), Belinostat/PXD101, Panobinostat/LBH-589, trichostatin A/TSA (7-[4-(dimethylamino) phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide), ITF2357, CBHA, Givinostat/ITF2357, romidepsin, PCI-24781, depsipeptide (FR901228 or FK228), butyrate, phenylbutyrate, valproic acid, AN-9, CI-994, Entinostat/MS-275, SNDX-275, mocetinostat/MGCD0103 (N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide), m-carboxycinnamic acid, bishydroxamic acid, suberic bishydroxamic acid, oxamflatin, ABHA, SB-55629, pyroxamide, propenamides, aroyl pyrrolyl hydroxamides, or LAQ824 (((E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide).

### Claim 3 (depends on 1)

The method of claim 1, wherein the HDAC inhibitor is a N-hydroxypyrimidine-5-carboxamide, wherein the HDAC inhibitor comprises an azabicyclo-hexane, wherein the HDAC inhibitor comprises a fluoroquinoline group, or wherein the HDAC inhibitor is a non-piperidine-containing pyrimidine hydroxamic acid derivative.

### Claim 4 (depends on 1)

The method of claim 1, wherein the DNA virus is a herpes virus.

### Claim 5 (depends on 4)

The method of claim 4, wherein the herpes virus is an Epstein-Barr virus.

### Claim 6 (depends on 1)

The method of claim 1, wherein the HDAC inhibitor and the antiviral agent are co-formulated.

### Claim 7 (depends on 1)

The method of claim 1, wherein the virally-induced condition is a cancerous condition, an inflammatory condition, an autoimmune condition, an allergic condition, or a skin condition.

### Claim 8 (depends on 1)

The method of claim 1, wherein the virally-induced condition is a lymphoma, chronic lymphocytic leukemia, nasopharyngeal carcinoma, gastric cancer, Kaposi's sarcoma, rheumatoid arthritis, systemic lupus erythematosus, or multiple sclerosis.

### Claim 9

A method for treating and/or preventing a viral condition, a virally-induced condition, or an inflammatory condition comprising administering a HDAC inhibitor and an antiviral agent wherein the MW of the HDAC inhibitor is greater than 275 g/mol.

### Claim 10 (depends on 9)

The method of claim 9, wherein the HDAC inhibitor is a N-hydroxypyrimidine-5-carboxamide, wherein the HDAC inhibitor comprises an azabicyclo-hexane, wherein the HDAC inhibitor comprises a fluoroquinoline group, or wherein the HDAC inhibitor is a non-piperidine-containing pyrimidine hydroxamic acid derivative.

### Claim 11 (depends on 10)

The method of claim 10, wherein the HDAC inhibitor is JNJ-26481585 (N-hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide), R306465/JNJ-16241199 (N-hydroxy-5-(4-(naphthalen-2-ylsulfonyl)piperazin-1-yl)pyrimidine-2-carboxamide), or CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide).

### Claim 12 (depends on 9)

The method of claim 9, wherein the viral or virally induced condition is caused by a herpes virus.

### Claim 13 (depends on 12)

The method of claim 12, wherein the herpes virus is an Epstein-Barr virus.

### Claim 14 (depends on 9)

The method of claim 9, wherein the HDAC inhibitor and the antiviral agent are administered simultaneously.

### Claim 15 (depends on 9)

The method of claim 9, wherein the HDAC inhibitor and the antiviral agent are administered orally.

### Claim 16 (depends on 15)

The method of claim 15, wherein the HDAC inhibitor is administered at 0.01-1 mg/kg per dose.

### Claim 17 (depends on 16)

The method of claim 16, wherein 1, 2, 3, or 4 doses are administered daily.

### Claim 18 (depends on 15)

The method of claim 15, wherein the total daily dosage of the HDAC inhibitor is no greater than about 200 mg.

### Claim 19 (depends on 15)

The method of claim 15, wherein the antiviral agent is valganciclovir and is administered at dose of 500-1500 mg/dose.

### Claim 20 (depends on 9)

The method of claim 9, wherein the HDAC inhibitor and the antiviral agent are co-formulated.

### Claim 21 (depends on 20)

The method of claim 20, wherein the co-formulation comprises a unit dose of no greater than 80 mg of the HDAC inhibitor and no greater than 1500 mg of the antiviral agent.

### Claim 22 (depends on 9)

The method of claim 9, wherein the viral condition or virally-induced condition is caused by a human immunodeficiency virus, a herpes virus, a parvovirus, a coxsackie virus, a Human T-lymphotropic virus, a BK virus, or a hepatitis virus.

### Claim 23 (depends on 9)

The method of claim 9, wherein the viral condition or virally-induced condition is caused by a retrovirus or a herpes virus.

### Claim 24 (depends on 23)

The method of claim 23, wherein the herpes virus is a herpes simplex virus, a herpes genitalis virus, a varicella zoster virus, an Epstein-Barr virus, a human herpes virus 6, a herpes virus type 1, herpes virus type 2, a human herpes virus type 8, or a cytomegalovirus.

### Claim 25 (depends on 24)

The method of claim 24, wherein the herpes virus is the Epstein-Barr virus.

### Claim 26 (depends on 9)

The method of claim 9, wherein the viral condition or virally-induced condition is caused by a DNA virus.

### Claim 27 (depends on 9)

The method of claim 9, wherein the viral condition or virally-induced condition is not caused by a retrovirus.

### Claim 28 (depends on 9)

The method of claim 9, wherein the virally-induced condition is a cancer, an inflammatory condition, an allergic condition, an autoimmune condition, or a skin condition.

### Claim 29 (depends on 9)

The method of claim 9, wherein the virally-induced condition is lymphoma, chronic lymphocytic leukemia, nasopharyngeal carcinoma, gastric cancer, Kaposi's sarcoma, rheumatoid arthritis, systemic lupus erythematosus, or multiple sclerosis.

### Claim 30 (depends on 9)

The method of claim 9, wherein the virally-induced condition is not sepsis or viremia.

### Claim 31 (depends on 9)

The method of claim 9, wherein the inflammatory condition is an autoimmune condition, and allergic condition, or a skin condition.

### Claim 32 (depends on 9)

The method of claim 9, wherein the HDAC inhibitor can penetrate the blood brain barrier.

### Claim 33 (depends on 9)

The method of claim 9, wherein the antiviral agent is a HIV drug, a Herpes drug, a CMV drug, or a hepatitis drug.

### Claim 34 (depends on 9)

The method of claim 9, wherein the antiviral agent is acyclovir, ganciclovir or valganciclovir.

### Claim 35 (depends on 9)

The method of claim 9, wherein the antiviral agent is not a heat shock protein inhibitor, an immunosuppressant, an antibiotic, a glucocorticoid, a non-steroidal anti-inflammatory drug, a Cox-2-specific inhibitor or a TNF-α binding protein.

### Claim 36 (depends on 9)

The method of claim 9, wherein the antiviral agent is not a Hsp90 inhibitor, tacrolimus, cyclosporin, rapamycin, methotrexate, cyclophosphamide, azathioprine, mercaptopurine, mycophenolate, FTY720, levofloxacin, amoxycillin, prednisone, cortisone acetate, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone, salicylates, arylalkanoic acids, a 2-arylpropionic acid, a N-arylanthranilic acid, an oxicam, a coxib, a sulphonanilide, valdecoxib, celecoxib, rofecoxib, leflunomide, gold thioglucose, gold thiomalate, aurofin, sulfasalazine, hydroxychloroquinine, minocycline, infliximab, etanercept, adalimumab, abatacept, anakinra, interferon-β, interferon-γ, interleukin-2, an allergy vaccine, an antihistamine, an antileukotriene, a beta-agonist, theophylline, or an anticholinergic.

### Claim 37 (depends on 9)

The method of claim 9, further comprising administering an additional agent.

### Claim 38 (depends on 37)

The method of claim 37, wherein the additional agent is an antiviral agent, a HDAC inhibitor, or a chemotherapeutic.

### Claim 39

A method for treating and/or preventing a viral condition, a virally-induced condition, or an inflammatory condition comprising administering a HDAC inhibitor and an antiviral agent, wherein the HDAC inhibitor is a pyrimidine hydroxamic acid derivative.

### Claim 40 (depends on 39)

The method of claim 39, wherein the HDAC inhibitor is a N-hydroxypyrimidine-5-carboxamide, wherein the HDAC inhibitor comprises an azabicyclo-hexane, wherein the HDAC inhibitor comprises a fluoroquinoline group, or wherein the HDAC inhibitor does not comprise a piperidine group.

### Claim 41 (depends on 39)

The method of claim 39, wherein the HDAC inhibitor and the antiviral agent are administered simultaneously.

### Claim 42 (depends on 39)

The method of claim 39, wherein the HDAC inhibitor and the antiviral agent are administered orally.

### Claim 43 (depends on 42)

The method of claim 42, wherein the antiviral agent is valganciclovir.

### Claim 44 (depends on 42)

The method of claim 42, wherein the HDAC inhibitor is administered at 0.2-2 mg/kg per dose.

### Claim 45 (depends on 44)

The method of claim 44, wherein 1, 2, 3, or 4 doses are administered daily.

### Claim 46 (depends on 42)

The method of claim 42, wherein the total daily dosage of the HDAC inhibitor is no greater than about 80 mg.

### Claim 47 (depends on 43)

The method of claim 43, wherein the valganciclovir is administered at dose of 900 mg/dose.

### Claim 48 (depends on 39)

The method of claim 39, wherein the HDAC inhibitor and the antiviral agent are co-formulated.

### Claim 49 (depends on 48)

The method of claim 48, wherein the co-formulation comprises a unit dose of no greater than 80 mg of the HDAC inhibitor and no greater than 1500 mg of the antiviral agent.

### Claim 50 (depends on 39)

The method of claim 39, wherein the viral condition or virally-induced condition is caused by a human immunodeficiency virus, a herpes virus, a parvovirus, a coxsackie virus, a Human T-lymphotropic virus, a BK virus, or a hepatitis virus.

### Claim 51 (depends on 50)

The method of claim 50, wherein the herpes virus is a herpes simplex virus, a herpes genitalis virus, a varicella zoster virus, an Epstein-Barr virus, a human herpes virus 6, a herpes virus type 1, herpes virus type 2, a human herpes virus type 8, or a cytomegalovirus.

### Claim 52 (depends on 39)

The method of claim 39, wherein the viral condition or virally-induced condition is caused by a DNA virus.

### Claim 53 (depends on 39)

The method of claim 39, wherein the viral condition or virally-induced condition is caused by an Epstein-Barr virus.

### Claim 54 (depends on 39)

The method of claim 39, wherein the viral condition or virally-induced condition is not caused by a retrovirus.

### Claim 55 (depends on 39)

The method of claim 39, wherein the virally-induced condition is a cancer, an inflammatory condition, an allergic condition, an autoimmune condition, or a skin condition.

### Claim 56 (depends on 39)

The method of claim 39, wherein the virally-induced condition is lymphoma, chronic lymphocytic leukemia, nasopharyngeal carcinoma, gastric cancer, Kaposi's sarcoma, rheumatoid arthritis, systemic lupus erythematosus, or multiple sclerosis.

### Claim 57 (depends on 39)

The method of claim 39, wherein the virally-induced condition is not sepsis or viremia.

### Claim 58 (depends on 39)

The method of claim 39, wherein the inflammatory condition is an autoimmune condition, and allergic condition, or a skin condition.

### Claim 59 (depends on 39)

The method of claim 39, wherein the HDAC inhibitor can penetrate the blood brain barrier.

### Claim 60 (depends on 39)

The method of claim 39, wherein the antiviral agent is a HIV drug, a Herpes drug, a CMV drug, or a hepatitis drug.

### Claim 61 (depends on 39)

The method of claim 39, wherein the antiviral agent is acyclovir, ganciclovir or valganciclovir.

### Claim 62 (depends on 39)

The method of claim 39, wherein the antiviral agent is not a heat shock protein inhibitor, an immunosuppressant, an antibiotic, a glucocorticoid, a non-steroidal anti-inflammatory drug, a Cox-2-specific inhibitor or a TNF-α binding protein.

### Claim 63 (depends on 39)

The method of claim 39, wherein the antiviral agent is not a Hsp90 inhibitor, tacrolimus, cyclosporin, rapamycin, methotrexate, cyclophosphamide, azathioprine, mercaptopurine, mycophenolate, FTY720, levofloxacin, amoxycillin, prednisone, cortisone acetate, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone, salicylates, arylalkanoic acids, a 2-arylpropionic acid, a N-arylanthranilic acid, an oxicam, a coxib, a sulphonanilide, valdecoxib, celecoxib, rofecoxib, leflunomide, gold thioglucose, gold thiomalate, aurofin, sulfasalazine, hydroxychloroquinine, minocycline, infliximab, etanercept, adalimumab, abatacept, anakinra, interferon-β, interferon-γ, interleukin-2, an allergy vaccine, an antihistamine, an antileukotriene, a beta-agonist, theophylline, or an anticholinergic.

### Claim 64 (depends on 39)

The method of claim 39, further comprising administering an additional agent.

### Claim 65 (depends on 64)

The method of claim 64, wherein the additional agent is an antiviral agent, a HDAC inhibitor, or a chemotherapeutic therapy.

### Claim 66

A method for treating and/or preventing a viral condition or a virally-induced condition comprising administering a HDAC inhibitor wherein the HDAC inhibitor is a pyrimidine hydroxamic acid derivative comprising an azabicyclo-hexane, or wherein the HDAC inhibitor is a non-piperidine-containing pyrimidine hydroxamic acid derivative.

### Claim 67 (depends on 66)

The method of claim 66, wherein the HDAC inhibitor is a pyrimidine hydroxamic acid derivative comprising an azabicyclo-hexane.

### Claim 68 (depends on 66)

The method of claim 66, wherein the HDAC inhibitor is a non-piperidine-containing pyrimidine hydroxamic acid derivative.

### Claim 69 (depends on 66)

The method of claim 66, wherein the HDAC inhibitor comprises a fluoroquinoline group.

### Claim 70 (depends on 66)

The method of claim 66, further comprising administering an antiviral agent.

### Claim 71 (depends on 70)

The method of claim 70, wherein the HDAC inhibitor and antiviral agent are administered simultaneously.

### Claim 72 (depends on 71)

The method of claim 71, wherein the HDAC inhibitor is administered orally.

### Claim 73 (depends on 72)

The method of claim 72, wherein the HDAC inhibitor is administered at 0.01-1 mg/kg per dose.

### Claim 74 (depends on 73)

The method of claim 73, wherein 1, 2, 3, or 4 doses are administered daily.

### Claim 75 (depends on 72)

The method of claim 72, wherein the total daily dosage of the HDAC inhibitor is no greater than about 200 mg.

### Claim 76 (depends on 71)

The method of claim 71, wherein the antiviral agent is administered at dose of 500-1500 mg/dose.

### Claim 77 (depends on 71)

The method of claim 71, wherein the HDAC inhibitor and the antiviral agent are co-formulated.

### Claim 78 (depends on 77)

The method of claim 77, wherein the co-formulation comprises a unit dose of no greater than 80 mg of the HDAC inhibitor and no greater than 1500 mg of the antiviral agent.

### Claim 79 (depends on 78)

The method of claim 78, wherein the antiviral agent is valganciclovir.

### Claim 80 (depends on 66)

The method of claim 66, wherein the viral condition or virally-induced condition is caused by a human immunodeficiency virus, a herpes virus, a parvovirus, a coxsackie virus, a Human T-lymphotropic virus, a BK virus, or a hepatitis virus.

### Claim 81 (depends on 80)

The method of claim 80, wherein the herpes virus is a herpes simplex virus, a herpes genitalis virus, a varicella zoster virus, an Epstein-Barr virus, a human herpes virus 6, a herpes virus type 1, herpes virus type 2, a human herpes virus type 8, or a cytomegalovirus.

### Claim 82 (depends on 81)

The method of claim 81, wherein the herpes virus is the Epstein-Barr virus.

### Claim 83 (depends on 66)

The method of claim 66, wherein the viral condition or virally-induced condition is caused by a DNA virus.

### Claim 84 (depends on 66)

The method of claim 66, wherein the viral condition or virally-induced condition is not caused by a retrovirus.

### Claim 85 (depends on 66)

The method of claim 66, wherein the virally-induced condition is a cancer, an inflammatory condition, an allergic condition, an autoimmune condition, or a skin condition.

### Claim 86 (depends on 66)

The method of claim 66, wherein the virally-induced condition is a lymphoma, chronic lymphocytic leukemia, nasopharyngeal carcinoma, gastric cancer, Kaposi's sarcoma, rheumatoid arthritis, systemic lupus erythematosus, or multiple sclerosis.

### Claim 87 (depends on 66)

The method of claim 66, wherein the virally-induced condition is not sepsis or viremia.

### Claim 88 (depends on 66)

The method of claim 66, wherein the HDAC inhibitor can penetrate the blood brain barrier.

### Claim 89 (depends on 70)

The method of claim 70, wherein the antiviral agent is a HIV drug, a Herpes drug, a CMV drug, or a hepatitis drug.

### Claim 90 (depends on 70)

The method of claim 70, wherein the antiviral agent is acyclovir, ganciclovir or valganciclovir.

### Claim 91 (depends on 70)

The method of claim 70, wherein the antiviral agent is not a heat shock protein inhibitor, an immunosuppressant, an antibiotic, a glucocorticoid, a non-steroidal anti-inflammatory drug, a Cox-2-specific inhibitor or a TNF-α binding protein.

### Claim 92 (depends on 70)

The method of claim 70, wherein the antiviral agent is not a Hsp90 inhibitor, tacrolimus, cyclosporin, rapamycin, methotrexate, cyclophosphamide, azathioprine, mercaptopurine, mycophenolate, FTY720, levofloxacin, amoxycillin, prednisone, cortisone acetate, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone, salicylates, arylalkanoic acids, a 2-arylpropionic acid, a N-arylanthranilic acid, an oxicam, a coxib, a sulphonanilide, valdecoxib, celecoxib, rofecoxib, leflunomide, gold thioglucose, gold thiomalate, aurofin, sulfasalazine, hydroxychloroquinine, minocycline, infliximab, etanercept, adalimumab, abatacept, anakinra, interferon-β, interferon-γ, interleukin-2, an allergy vaccine, an antihistamine, an antileukotriene, a beta-agonist, theophylline, or an anticholinergic.

### Claim 93 (depends on 70)

The method of claim 70, further comprising administering an additional agent.

### Claim 94 (depends on 93)

The method of claim 93, wherein the additional agent is an antiviral agent, a HDAC inhibitor, or a chemotherapeutic therapy.

### Claim 95

A composition comprising a (i) HDAC inhibitor and (ii) an antiviral agent wherein the HDAC inhibitor is a pyrimidine hydroxamic acid derivative.

### Claim 96 (depends on 95)

The composition of claim 95, wherein the HDAC inhibitor is JNJ-26481585 (N-hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide), R306465/JNJ-16241199 (N-hydroxy-5-(4-(naphthalen-2-ylsulfonyl)piperazin-1-yl)pyrimidine-2-carboxamide), or CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide).

### Claim 97 (depends on 95)

The composition of claim 95, wherein the HDAC inhibitor is not m-carboxycinnamic acid, bishydroxamic acid, suberic bishydroxamic acid, Trichostatin A (7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide), SAHA (suberoyl anilide hydroxamic acid)/Vorinostat, oxamflatin, ABHA, SB-55629, pyroxamide, propenamides, aroyl pyrrolyl hydroxamides, Belinostat/PXD101,Papobinostat, LAQ 824 (((E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide), LBH589, or TSA.

### Claim 98 (depends on 95)

The composition of claim 95, wherein the HDAC inhibitor can penetrate the blood brain barrier.

### Claim 99 (depends on 95)

The composition of claim 95, wherein the antiviral agent is a HIV drug, a Herpes drug, a CMV drug, or a hepatitis drug.

### Claim 100 (depends on 95)

The composition of claim 95, wherein the antiviral agent is acyclovir, ganciclovir or valganciclovir.

### Claim 101 (depends on 95)

The composition of claim 95, wherein the antiviral agent is not a heat shock protein inhibitor, an immunosuppressant, an antibiotic, a glucocorticoid, a non-steroidal anti-inflammatory drug, a Cox-2-specific inhibitor or a TNF-α binding protein.

### Claim 102 (depends on 95)

The composition of claim 95, wherein the antiviral agent is not a Hsp90 inhibitor, tacrolimus, cyclosporin, rapamycin, methotrexate, cyclophosphamide, azathioprine, mercaptopurine, mycophenolate, FTY720, levofloxacin, amoxycillin, prednisone, cortisone acetate, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone, salicylates, arylalkanoic acids, a 2-arylpropionic acid, a N-arylanthranilic acid, an oxicam, a coxib, a sulphonanilide, valdecoxib, celecoxib, rofecoxib, leflunomide, gold thioglucose, gold thiomalate, aurofin, sulfasalazine, hydroxychloroquinine, minocycline, infliximab, etanercept, adalimumab, abatacept, anakinra, interferon-β, interferon-γ, interleukin-2, an allergy vaccine, an antihistamine, an antileukotriene, a beta-agonist, theophylline, or an anticholinergic.

### Claim 103 (depends on 95)

The composition of claim 95, further comprising an additional agent.

### Claim 104 (depends on 103)

The composition of claim 103, wherein the additional agent is an antiviral agent, a HDAC inhibitor, or a chemotherapeutic drug.

### Claim 105 (depends on 95)

The composition of claim 95, wherein the HDAC inhibitor and the antiviral agent are in an oral formulation.

### Claim 106 (depends on 105)

The composition of claim 105, wherein the HDAC inhibitor is present at 0.01-1 mg/kg per dose.

### Claim 107 (depends on 105)

The composition of claim 105, wherein the formulation comprises a unit dose of no greater than 80 mg of the HDAC inhibitor and no greater than 1500 mg of the antiviral agent.

### Claim 108

A method for treating and/or preventing a virus-induced inflammatory condition in a subject comprising administering a viral inducing agent and an antiviral agent to the subject, thereby treating and/or preventing the inflammatory condition.

### Claim 109 (depends on 108)

The method of claim 108, wherein the virus is a member of the herpes virus family, human immunodeficiency virus, parvovirus, or coxsackie virus.

### Claim 110 (depends on 109)

The method of claim 109, wherein the member of the herpes virus family is herpes simplex virus, herpes genitalis virus, varicella zoster virus, Epstein-Barr virus, human herpesvirus 6, or cytomegalovirus.

### Claim 111 (depends on 110)

The method of claim 110, wherein the member of the herpes virus family is Epstein-Barr virus, cytomegalovirus, or human herpesvirus 6.

### Claim 112 (depends on 108, 109, 110)

The method of claim 108, 109, 110, or 111, wherein the inflammatory condition is an autoimmune condition.

### Claim 113 (depends on 112)

The method of claim 112, wherein the autoimmune condition is rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, systemic lupus erythematosus, autoimmune hepatitis, autoimmune thyroiditis, hemophagocytic syndrome, diabetes, Crohn's condition, ulcerative colitis, psoriasis, psoriatic arthritis, idiopathic thrombocytonpenic pupura, polymyositis, dermatomyositis, myasthenia gravis, autoimmune thryroiditis, Evan's syndrome, autoimmune hemolytic anemia, aplastic anemia, autoimmune neutropenia, scleroderma, Reiter's syndrome, ankylosing spondylitis, pemphnigus, pemphigoid or autoimmune hepatitis.

### Claim 114 (depends on 108)

The method of claim 108, wherein the inflammatory condition is an allergic condition.

### Claim 115 (depends on 108)

The method of claim 108, wherein the inflammatory condition is a skin condition.

### Claim 116 (depends on 108)

The method of claim 108, wherein the inflammatory condition is associated with coronary artery condition or peripheral artery condition.

### Claim 117 (depends on 108)

The method of claim 108, wherein the inflammatory condition is retinitis, pancreatitis, cardiomyopathy, pericarditis, colitis, glomerulonephritis, lung inflammation, esophagitis, gastritis, duodenitis, ileitis, meningitis, encephalitis, encephalomyelitis, transverse myelitis, cystitis, urethritis, mucositis, lymphadenitis, dermatitis, hepatitis, osteomyelitis, or herpes zoster.

### Claim 118 (depends on 116)

The method of claim 116, wherein the inflammatory condition is atherosclerosis.

### Claim 119 (depends on 116)

The method of claim 116, wherein the virus is cytomegalovirus or herpes simplex virus.

### Claim 120 (depends on 108)

The method of claim 108, wherein the viral inducing agent is one or more of a chemotherapeutic drug, HDAC inhibitor, or DNA demethylating agent.

### Claim 121 (depends on 120)

The method of claim 120, wherein the HDAC inhibitor is butyrate or MS-275.

### Claim 122 (depends on 108)

The method of claim 108, wherein the viral inducing agent can penetrate the blood brain barrier.

### Claim 123 (depends on 122)

The method of claim 122, wherein the viral inducing agent comprises arginine butyrate.

### Claim 124 (depends on 108)

The method of claim 108, wherein the antiviral agent is ganciclovir or valganciclovir.

### Claim 125 (depends on 108)

The method of claim 108, further comprising administering an additional agent.

### Claim 126 (depends on 125)

The method of claim 125, wherein the additional agent comprises a vaccine.

### Claim 127 (depends on 126)

The method of claim 126, wherein the vaccine comprises myelin basic protein and the condition is multiple sclerosis.

### Claim 128 (depends on 126)

The method of claim 126, wherein the vaccine comprises an antigen and the condition is diabetes.

### Claim 129 (depends on 125)

The method of claim 125, wherein the additional agent is aspirin, naproxen, ibuprofen, or a statin.

### Claim 130 (depends on 125)

The method of claim 125, wherein the inflammatory condition is an autoimmune condition and the additional agent is cyclosporine, azathiorprine, methotrexate, cyclophosphamide, FK506, tacrolimus, monoclonal antibody, anti-T cell monoclonal antibody, anti-B cell monoclonal antibody, IL-2 receptor antibody, or a TNF inhibitor.

### Claim 131 (depends on 130)

The method of claim 130, wherein the monoclonal antibody is an anti-B cell antibody.

### Claim 132 (depends on 131)

The method of claim 131, wherein the anti-B cell antibody is anti-CD20.

### Claim 133 (depends on 130)

The method of claim 130, wherein the anti-T cell antibody is an anti-CD3 antibody.

### Claim 134 (depends on 133)

The method of claim 133, wherein the anti-CD3 antibody is OKT3.

### Claim 135 (depends on 130)

The method of claim 130, wherein the TNF inhibitor is infliximab (Remicade™), etanercept (Enbrel™), adalimumab (Humira™), or an anti-IL-6 antibody.

### Claim 136 (depends on 125)

The method of claim 125, wherein the inflammatory condition is atherosclerosis and the additional agent is a lipid lowering agent.

### Claim 137 (depends on 136)

The method of claim 136, wherein the lipid lowering agent is rosuvastatin, atorvastatin, simvastatin, or lovastatin.

### Claim 138 (depends on 125)

The method of claim 125, wherein the inflammatory condition is multiple sclerosis and the additional agent is mitoxantrone, cladribine, or Campath antibody.

### Claim 139 (depends on 108)

The method of claim 108, wherein the viral inducing agent is administered to the subject before the antiviral agent.
